Akamis Bio

Industry · 11 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer Locally Advanced Rectal Cancer (LARC)	Phase 1	2025-04-07
Completed	Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) Epithelial Tumor, Metastatic Cancer	Phase 1	2022-04-13
Completed	Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours Metastatic Cancer, Epithelial Tumor	Phase 1	2021-12-01
Completed	A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck Squamous Cell Carcinoma of the Head and Neck	Phase 1	2021-11-04
Completed	First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector Metastatic Cancer, Epithelial Tumor	Phase 1	2020-01-23
Completed	First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) Metastatic Cancer, Epithelial Tumor	Phase 1	2019-02-19
Completed	Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor	Phase 1	2016-01-25
Completed	Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients Recurrent Platinum Resistant Ovarian Cancer	Phase 1	2014-06-01
Completed	Mechanism of Action Trial of ColoAd1 Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer	Phase 1	2013-06-01
Completed	Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer	Phase 1 / Phase 2	2012-09-20
Completed	A Clinical Study With MT-102 in Subjects With Cancer Cachexia Cancer Cachexia	Phase 2	2011-04-01